http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-611805-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e673458c8c443e6fcd34bbc9565bf7f7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-91205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-44 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5026 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2012-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a51cd51b95a6a81eff12bdd2a3531183 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48d8b426bf7fb1a825cd357ccf8ba91f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_366b434f56b0d2e9eed5206a86d5f39e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3701a1caf093ca56cfb3e8fa9396a53a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_974f5d5d43a791a3187e25efaba2e36a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_190103d30926a65b0995b618a2f18f9d |
| publicationDate | 2015-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-611805-A |
| titleOfInvention | Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles |
| abstract | Disclosed is the use of BUBR1 as a biomarker for predicting the response to a compound, wherein the compound is a compound of general formula I (see abstract drawing) wherein - R represents phenyl, thienyl or pyridinyl - wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; - and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen; - X represents a group C=Y, wherein Y stands for oxygen or nitrogen substituted by hydroxy or lower alkoxy; - R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; - R2, R3 and R6 represent hydrogen; - R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower alkoxy; - or R4 and R5 together represent methylenedioxy; - and pharmaceutically acceptable salts, solvates, polymorphs, prodrugs and salts of prodrugs thereof; - or wherein - R represents phenyl or pyridinyl - wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; - and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen; - X represents oxygen; - R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; - R2, R3 and R6 represent hydrogen; - R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower alkoxy; - or R4 and R5 together represent methylenedioxy; - and pharmaceutically acceptable salts, solvates, polymorphs, prodrugs and salts of prodrugs thereof, - and wherein the prefix lower denotes a radical having up to and including a maximum of 7 carbon atoms, and wherein the response is of a disease in a subject and the biomarker BUBR1 is measured ex vivo in a sample or samples taken from the human or animal body. |
| priorityDate | 2011-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 246.